Trial Profile

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 13 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Erlotinib (Primary) ; Gefitinib (Primary) ; Osimertinib (Primary) ; Ramucirumab (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms RELAY
Sponsors Eli Lilly and Company

09 Jan 2025 Planned End Date changed from 16 Dec 2024 to 1 Dec 2025.
30 May 2024 This study has been completed in Germany, according to European Clinical Trials Database record.
15 Mar 2024 Planned End Date changed from 16 Dec 2023 to 16 Dec 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com